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Abstract
Background: India has 2.0 million estimated tuberculosis (TB) cases per annum with an estimated 280,000 TB-
related deaths per year. Understanding when in the course of TB treatment patients die is important for
determining the type of intervention to be offered and crucially when this intervention should be given. The
objectives of the current study were to determine in a large cohort of TB patients in India:- i) treatment outcomes
including the number who died while on treatment, ii) the month of death and iii) characteristics associated with
“early” death, occurring in the initial 8 weeks of treatment.
Methods: This was a retrospective study in 16 selected Designated Microscopy Centres (DMCs) in Hyderabad,
Krishna and Adilabad districts of Andhra Pradesh, South India. A review was performed of treatment cards and
medical records of all TB patients (adults and children) registered and placed on standardized anti-tuberculosis
treatment from January 2005 to September 2009.
Results: There were 8,240 TB patients (5183 males) of whom 492 (6%) were known to have died during treatment.
Case-fatality was higher in those previously treated (12%) and lower in those with extra-pulmonary TB (2%). There
was an even distribution of deaths during anti-tuberculosis treatment, with 28% of all patients dying in the first 8
weeks of treatment. Increasing age and new as compared to recurrent TB disease were significantly associated
with “early death”.
Conclusion: In this large cohort of TB patients, deaths occurred with an even frequency throughout anti-TB
treatment. Reasons may relate to i) the treatment of the disease itself, raising concerns about drug adherence,
quality of anti-tuberculosis drugs or the presence of undetected drug resistance and ii) co-morbidities, such as HIV/
AIDS and diabetes mellitus, which are known to influence mortality. More research in this area from prospective
and retrospective studies is needed.
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Background
National TB Control Programmes (NTPs) routinely
report treatment outcomes for patients with tuberculosis
(TB). This is reflected in national reports and also
annual reports from the World Health Organization
(WHO) which provide data on treatment outcomes of
TB patients from all countries in the world. Treatment
outcomes include death, which is defined as death from
any cause occurring during the course of anti-TB
treatment.
There have been a few publications on the timing of
death in patients while on treatment. In sub-Saharan
Africa, studies have shown that the majority of deaths
occur early during the first 1-2 months of anti-tubercu-
losis treatment [1-3]. In sub-Saharan Africa, where co-
infection with HIV is high, this information has been
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death rates during treatment. For example, giving antire-
troviral therapy (ART) during the initial phase rather
than the continuation phase of anti-tuberculosis treat-
ment is more beneficial in reducing death rates in co-
infected TB patients, and is based on a sound knowl-
edge of when HIV-infected TB patients die [4,5]. Similar
reports of early deaths have come from more industria-
lised countries such as Singapore [6], Russia [7] and Tai-
wan [8].
India, with a total population of 1.2 billion, has a well
established national TB control programme, based
firmly on the “DOTS” strategy, and treatment outcomes
are reported regularly for patients with all types of TB
[9]. India has an estimated 2.0 million incident TB cases
each year, and an estimated TB-related mortality of
280,000 deaths per annum [9]. Understanding when in
the course of TB treatment patients die is important for
determining the type of intervention to be offered and
crucially when this intervention should be given. Such
information might be useful in further reducing case
fatality rates among TB patients. There has been pre-
vious work carried out in India between 1999 and 2000
and in 2004 looking at timing of death as part of studies
that assessed risk factors for death, failure and default,
and between 50-65% of deaths were reported to occur
within the initial phase of treatment [10,11]. However,
each of these studies assessed less than 750 patients. As
a result, there were small numbers of patients who died,
and the findings may not be representative of the wider
or more recent picture of timing of deaths during anti-
tuberculosis treatment in India within the Revised
National TB Control Programme (RNTCP).
The aim of this study was to document the timing of
reported death in a large cohort of patients with tuber-
culosis who die during treatment. The specific objec-
tives were to determine in a defined cohort of TB
patients:- i) the treatment outcomes and the number
who died while on treatment, ii) the month of death
and iii) the characteristics of patients who were recorded
as having died early in the initial 8 weeks of anti-tuber-
culosis treatment.
Methods
Study design and setting
This was a descriptive retrospective study based on
record reviews and adhered to the methodological guide-
lines recommended in the STROBE document on obser-
vational studies [12]. The study was carried out in 16
selected Designated Microscopy Centres (DMCs) in
Hyderabad, Krishna and Adilabad districts of Andhra
Pradesh, South India. These centres were selected
because activities are implemented by LEPRA India in
partnership with 4 district TB control societies. TB
treatment is initiated in India in accordance with the
RNTCP DOTS strategy and, according to this strategy at
the time; patients were placed on one of 3 categories for
treatment [13]. The duration of treatment for patients in
category 1, II or III varied from 6-8 months. Treatment
outcomes were obtained for all patients registered during
each quarter, 15 months after the start of treatment.
Participants
All TB patients (adults and children) registered and
placed on standardised anti-tuberculosis treatment in
quarterly periods from January 2005 to September 2009
in the selected 16 DMCs situated in Hyderabad, Krishna
and Adilabad in Andhra Pradesh, South India were
included in the study.
Source of data, variables and data collection instrument
Data were collected from the TB patient treatment card
and follow-up records at the DMC, which in turn were
cross checked with RNTCP Tuberculosis Unit TB regis-
ters. The following information was obtained:- TB regis-
tration number, age, sex, occupation, type of TB
(Pulmonary TB- PTB and extra pulmonary TB - EPTB),
category of treatment and HIV-serostatus. Treatment
outcomes were recorded, including death during anti-
TB treatment. In those who died, the timing of death
was recorded as occurring at 4 week intervals from start
to completion of treatment. A structured questionnaire
w a sp r e p a r e da n dp i l o tt e s t e di n1 0 %o ft h ep a t i e n t
records. This questionnaire was subsequently revised,
and used to capture all data variables for the study.
Analysis and statistics
Data were entered into an Excel file (MS Excel 2003),
and were analysed using SPSS version 18 software. The
chi-squared test was used to compare groups while the
chi-square for trend was used to examine linear trends.
Measures of risk were determined using odds ratios
(OR) and 95% confidence intervals, with the level of sig-
nificance set at P < 0.05.
Ethics approval
This study proposal was approved by The Union Ethics
Advisory Group, the Ethics committee of the Public
Health Foundation of India and the LEPRA India -
Institutional Ethical Committee. Permission was
received from State TB Officer, Andhra Pradesh to carry
out the study.
Results
There were 8,240 TB patients (5183 men) whose mean
age was 36 (SD 16) years. The treatment outcomes for
all patients and also stratified by type and category of
TB are shown in Table 1. Case fatality rates were 6% in
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tive pulmonary TB (PTB). Compared with patients who
had new smear-positive PTB, case fatality rates were sig-
nificantly lower at 1.6% in those with extra-pulmonary
TB (EPTB) [RR 0.26, 95% CI 0.18-0.37, P < 0.001] and
significantly higher at 12% in those with previously trea-
ted TB on a retreatment regimen [RR 1.93, 95% CI
1.58-2.36, P < 0.001].
Timing of death in all TB patients during the course
of anti-tuberculosis treatment is shown in Table 2, and
the survival analysis curve with 3 line graphs stratified
for all TB patients and patients with new and retreat-
ment TB is shown in Figure 1. There was a fairly even
distribution of deaths during the course of anti-tubercu-
losis treatment, with a lower proportion of patients
dying in the four-week periods after 6 months (these
patients were those on the longer retreatment regimens
and those who were being treated for severe types of
EPTB such as TB meningitis and TB spine). Patient
characteristics associated with “early deaths” (i.e., dying
in the first 8 weeks of treatment) are shown in Table 3.
There was an increased odds of early death associated
with age above 50 years, and in new patients and those
treated with category 1 and 3 regimens there was an
increased risk of early death compared with patients
who had previously treated TB. Otherwise, gender,
occupation and HIV status (including a comparison of
HIV status known compared with HIV status not
known) showed no significant association.
Discussion
This study in a large cohort of over 8,000 registered TB
patients found a low case fatality at almost 6%. Patients
with previously treated TB had higher death rates and
those with EPTB had lower deaths rates than those with
new pulmonary tuberculosis. The higher death rates in
previously treated patients might be explained by more
severe and drug resistant disease consequent upon failed
first line therapy or initial and undiagnosed multi-drug
resistant TB [13,14]. Although we did not document the
types of EPTB during this study, the majority of patients
in India with EPTB have lymph node disease [13],
which tends to be associated with morbidity but not
mortality.
There was a fairly even distribution of deaths during
the course of anti-tuberculosis treatment. This is in
marked contrast to the situation in sub-Saharan Africa
where there is an excess of deaths in the first 1-2
months of treatment, thought to be due to late presen-
tation and therefore severe tuberculosis disease as well
as the effects of advanced HIV disease in those who are
co-infected [3,4]. The two main characteristics
Table 1 Treatment Outcomes in all TB patients and in relation to type and category of TB, Andhra Pradesh, India
All TB Patients Registered on Treatment Treatment success (%) Death (%) Default (%) Transfer Out (%) Failure (%)
NSP 3404 2996 (88%) 211 (6%) 153 (5%) 28 (< 1%) 16 (< 1%)
NSN 1663 1497 (90%) 103 (6%) 49 (3%) 11 (< 1%) 3 (< 1%)
EPTB 1945 1796 (92%) 31 (2%) 86 (4%) 31 (2%) 1 (< 1%)
Previously treated 1228 860 (70%) 147 (12%) 160 (13%) 32 (3%) 29 (2%)
Total 8240 7149 (87%) 492 (6%) 448 (5%) 102 (1%) 49 (< 1%)
NSP New Smear-Positive Pulmonary TB
NSN New Smear-Negative PTB
EPTB New Extra Pulmonary TB
Previously treated - previous TB which was treated with a standardised retreatment regimen
Table 2 Timing of death in patients who were recorded as having died during anti-tuberculosis treatment, Andhra
Pradesh, India
Deaths reported in weeks from start of treatment Deaths Cumulative frequency
N%N %
0-4 weeks 70 14 70 14
5-8 weeks 69 14 139 28
9-12 weeks 76 15 215 43
13-16 weeks 83 17 298 60
17-20 weeks 60 12 358 72
21-24 weeks 61 13 419 85
25-28 weeks 46 9 465 94
29 weeks and above 27 6 492 100.0
Total 492 100 492 100
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Indian study were age above 50 years and new disease
compared with previously treated disease. Increasing age
has been noted as a risk factor for death in other studies
both within India [10,15] and outside of India [2], and
new disease in contrast to recurrent disease was also
associated with high early mortality during the first 4
weeks of treatment in Malawi [2]. Why this occurs is
not known. Older people may be at higher risk of co-
morbid disease which may result in a more serious ill-
ness at the time of presentation, diagnosis and treat-
ment, and they may also develop chronic respiratory
illnesses resembling and mistaken for smear-negative
PTB due to chronic bronchitis and lung cancer [16].
Patients with recurrent disease may also be familiar with
t h es y m p t o m sa n ds i g n so fT B ,a n dt h e r e f o r ep r e s e n t
earlier than those with new disease and as a result have
less risk of early death. HIV-serostatus was not asso-
ciated with “early deaths” in the small sample of patients
who were HIV-tested, although many patients in the
study were not HIV tested.
Why is there a difference in distribution of deaths in
India compared with sub-Saharan Africa? First and most
importantly, it will be necessary to repeat this study in
other parts of the country and in large numbers of
patients to ensure that the results in Andhra Pradesh
are nationally representative. If indeed the results are
confirmed, then there may be various explanations.
I n d i ah a sap r o b l e mw i t hi n i t ial defaulters [17] i.e.,
patients who are diagnosed with active TB but fail to
get registered and placed on treatment. A high initial
default rate will falsely lower early death rates in regis-
tered TB patients, obscuring the true picture of patients
dying early during the registration and first few weeks of
treatment of their disease. Second, HIV co-infection is
lower in India than in Africa, with national rates of
HIV-infection in TB patients currently at 5-10% [9].
Untreated, advanced HIV disease is therefore not an
important factor in India, while in sub-Saharan Africa
this has played a major role in case fatality and early
deaths, and to some extent this has been mitigated by
the introduction of cotrimoxazole preventive therapy
and antiretroviral therapy.
If death rates are truly dispersed in an even manner
during the course of anti-TB treatment in India then
more work needs to be done in this area. Reasons may
relate to the treatment of the disease itself, raising con-
cerns about drug adherence, quality of anti-tuberculosis
Figure 1 Survival Curves for all TB patients and patients with new and retreatment TB.
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They may also relate to co-morbidities which influence
mortality. For example, diabetes mellitus has been calcu-
lated to account for 15%-20% of pulmonary TB in India
[18], and there is growing evidence that diabetes is asso-
ciated with an increased case fatality in TB patients
[19-21]. The timing of death in diabetes patients who
have TB is not known and requires active research, but
one could speculate that diabetes exerts its negative
effects throughout the course of anti-TB treatment as a
result of drug-drug interactions, an increased association
with anti-tuberculosis drug toxicity and immune sup-
pressive effects of diabetes.
The strengths of this study are that there were a large
number of patients enrolled in the cohort and treatment
outcomes were tracked and recorded using standardised
systems. However, there are a number of limitations.
First, this was a record review and it is possible that
mistakes were made in the recording of timing and date
of death. Second, patients who are recorded as default
or transfer out may also have died [15], and such mis-
classification may affect the results. Third, the records
that formed the source of data did not contain valuable
information such as results of any culture and drug sen-
sitivity testing, which might have been important in
explaining reasons for some of the deaths. Fourth, the
16 selected sites were all supported by LEPRA partner-
ing with RNTCP, and as such may not be representative
of other sites where this support was absent.
Whatever the shortcomings of this study, the results
should serve to encourage others to repeat similar stu-
dies in other parts of the country and should also
encourage programme staff to carefully record timing of
death and timing of other adverse events such as default
and transfer out. A number of potentially important
measures might help to reduce death rates by ensuring
that i) all patients diagnosed with smear-positive sputum
are registered and start anti-TB treatment as soon as
possible (thereby cutting down initial default rates) [22],
ii) patients who are at risk of drug resistance, such as
Table 3 Characteristics of patients with “early” deaths reported during anti-tuberculosis treatment, Andhra Pradesh,
India
Characteristics Early deaths < 8 weeks All deaths during treatment Odds Ratio (95% Confidence Intervals)
Gender Number % Number
Male 102 28 363 OR 0.97 (0.6-1.6) P = 0.89
Female 37 29 129 Reference = 1
Age
< 14 years 2 25 8 Chi-square test for trend = 5.668 P = 0.018
15-29 years 23 23 102
30-49 years 55 26 216
> 50+ 59 36 166
Occupation
Skilled 11 18 61 Reference
Semi-skilled 22 28 79 OR 1.75 (0.7-4.3) P = 0.17
Manual 106 30 352 OR 1.96 (0.9-4.2) P = 0.05
Type of TB
New smear-positive PTB 70 33 211 OR 2.0 (1.2-3.4) P < 0.01
New smear-negative PTB 28 27 103 OR 1.52 (0.8-2.9) P = 0.17
New EPTB 12 39 31 OR 2.57 (1.0-6.4) P = 0.02
Previously Treated TB 29 20 147 Reference = 1
Treatment Category
Category 1 (New) 84 31 272 OR 1.82 (1.1-3.0) P = 0.01
Category 3 (New) 26 36 73 OR 2.2 (1.1-4.4) P = 0.01
Category 2 (Retreatment) 29 20 147 Reference = 1
HIV status
HIV-positive 22 22 98 OR 0.82 (0.4-1.6) P = 0.53
HIV-negative 40 26 154 Reference = 1
HIV- status unknown 77 32 240 Not tested
Total 139 28 492
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ity testing so that treatment is appropriately tailored to
levels of drug resistance, and iii) elderly patients are
investigated for co-morbidities including diabetes melli-
tus which may increase the risk of death during treat-
ment [23]. A better understanding of when and why the
estimated 280,000 annual TB-related deaths occur is
essential as India strives to improve programme perfor-
mance and exceed the new 2015 global targets of treat-
ment success rates of 90% in the years to come [24].
Conclusions
In this large cohort of TB patients registered in Andhra
Pradesh, South India, deaths occurred with an even fre-
quency throughout anti-TB treatment. Reasons may
relate to i) the treatment of the disease itself, raising
concerns about drug adherence, quality of anti-tubercu-
losis drugs or the presence of undetected drug resis-
tance and ii) co-morbidities, such as HIV/AIDS and
diabetes mellitus, which are known to influence mortal-
ity. More research in this area from prospective and ret-
rospective studies is needed.
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